Bispecific T-cell engaging antibodies targeting DLL3 [50], such as tarlatamab [47], may be particularly beneficial for tailoring therapy for the neuroendocrine SCLC-A and SCLC-N subtypes, in which DLL3 expression is higher and MHC I expression is lower. This evidence concerns the gene DLL3 and small cell lung carcinoma.